YES In this analysis from the atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) Triage Study (ALTS), 33 of 621 women who had a diagnosis of cervical intraepithelial neoplasia (CIN) 3 at baseline also tested negative for high-risk human papillomavirus (HPV) DNA.
When it comes to cervical cancer prevention, screening and diagnostic tests have limits to their accuracy. Cancer-prevention strategies work because we assess patients over time and because we accept a small number of false positives as necessary to minimize the loss of sensitivity; in that way, we also minimize cancer-related morbidity.1
Link between high-risk HPV and cancer is a given
Cervical cancer is invariably linked to high-risk HPV. Women who are not truly infected with high-risk HPV are believed to have no risk for cervical cancer.2 Assay-based endpoints such as HPV DNA testing have good accuracy indices, whereas cytologic and histologic endpoints are subject to greater human error.
A CIN 3 lesion should never occur in a woman who is negative for high-risk HPV DNA. When the combination is found, which is rare, one of two mechanisms is involved:
- a falsely negative HPV test
- a falsely positive diagnosis of CIN 3.
In ALTS, falsely positive histology was probably to blame
The CIN 3 detected in women who tested negative for high-risk HPV DNA (i.e., after borderline cytology rather than because of a high-grade squamous intraepithelial lesion [HSIL]) was probably associated with falsely positive histology rather than falsely negative HPV testing.
CIN 3 in women who tested negative for high-risk HPV DNA was more likely to be:
- diagnosed at exit
- from a center where CIN 3 diagnoses were not confirmed by the Pathology
and less likely to be:
- associated with a referral Pap test classified as LSIL than as ASCUS
- associated with an enrollment Pap test classified as HSIL
- associated with high-grade Cervigrams.
These women also were likely to test negative for HPV DNA using Linear Array.
In reviewing cases of CIN 3 in the 33 women who tested negative for high-risk HPV DNA, investigators found only 8 cases attributable to falsely-negative HPV testing, whereas 12 were related to incident HPV infection. Eight cases were caused by histologic overcall; 5 represented non–high-risk HPV that was unlikely to progress to cancer.
HPV testing has good, though not perfect, sensitivity for CIN 3. These findings certainly do not suggest that HPV testing is insufficiently accurate for clinical use.
Counsel women who have borderline cytology and who test negative for high-risk HPV to undergo continued testing according to the guidelines of the American Society for Colposcopy and Cervical Pathology.—DAVID G. MUTCH, MD